An OA phenotype may obtain major benefit from bone-acting agents.

A particular subset of postmenopausal patients with high remodeling and/or low subchondral bone density may benefit from the treatment with bone-acting agents hindering OA progression.

This OA population could be identified with the simultaneous use of subchondral bone dual-energy X-ray absorptiometry and scintigraphy.

Autor: Roman-Blas JA, Castañeda S, Largo R, Lems WF, Herrero-Beaumont G.

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada